

## Posttransplant lymphoproliferative disorders in neuronal xenotransplanted macaques

Cavicchioli, L. ; Ferraresso, S.; Westmoreland, S.; Kaliyaperumal, S.; Knight, H.; Crossan, C.; Scobie, L.; Danesi, A.; Vadori, M.; Trez, D.; Aron Badin, R.; Hantraye, P.; Cozzi, E.

*Published in:*  
Veterinary Pathology

*DOI:*  
[10.1177/0300985816669407](https://doi.org/10.1177/0300985816669407)

*Publication date:*  
2017

*Document Version*  
Author accepted manuscript

[Link to publication in ResearchOnline](#)

### *Citation for published version (Harvard):*

Cavicchioli, L, Ferraresso, S, Westmoreland, S, Kaliyaperumal, S, Knight, H, Crossan, C, Scobie, L, Danesi, A, Vadori, M, Trez, D, Aron Badin, R, Hantraye, P & Cozzi, E 2017, 'Posttransplant lymphoproliferative disorders in neuronal xenotransplanted macaques', *Veterinary Pathology*, vol. 54, no. 2, pp. 336-344.  
<https://doi.org/10.1177/0300985816669407>

### **General rights**

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

### **Take down policy**

If you believe that this document breaches copyright please view our takedown policy at <https://edshare.gcu.ac.uk/id/eprint/5179> for details of how to contact us.

## **Post-transplant lymphoproliferative disorders in neuronal xenotransplanted macaques**

L. Cavicchioli<sup>1</sup>, S. Ferraresso<sup>1</sup>, S. Westmoreland<sup>2</sup>, S. Kaliyaperumal<sup>2</sup>, H. Knight<sup>2</sup>, C. Crossan<sup>3</sup>, L. Scobie<sup>3</sup>, A. Danesi<sup>1</sup>, M. Vadori<sup>4</sup>, D. Trez<sup>1</sup>, R. Aron Badin<sup>5</sup>, P. Hantraye<sup>5</sup>, E. Cozzi<sup>4,6</sup>

<sup>1</sup>Department of Comparative Biomedicine and Food Science, Padova University, Italy (LC, SF, AD, RZ)

<sup>2</sup>New England Primate Research Center, Southborough, MA, USA (SW, SK, HK)

<sup>3</sup>Caledonian University, Glasgow, UK (CC, LS)

<sup>4</sup>CORIT, Padova, Italy (MV, EC)

<sup>5</sup>MIRCE, CEA UMR 9199, Fontenay-aux-Roses, France (RAB, PH)

<sup>6</sup>Padova General Hospital, Italy (EC)

### Corresponding author:

Laura Cavicchioli

Department of Comparative Biomedicine and Food Science

University of Padua

Viale dell'Università 16

35020 Legnaro-PD-Italy

phone: +39 049 827 2962

fax: +39 049 827 2973

[laura.cavicchioli@unipd.it](mailto:laura.cavicchioli@unipd.it)

## **Abstract**

Post-transplant lymphoproliferative disorders (PTLD) are a heterogeneous group of lymphoid proliferations that occur in the setting of depressed T-cell function due to immunosuppressive therapy used following solid organ transplantation, hematopoietic stem cell transplantation and also xenotransplantation. In the present study, 28 immunosuppressed parkinsonian *Macaca fascicularis* were intracerebrally injected with wild-type or CTLA4-Ig transgenic porcine xenografts to identify a suitable strategy to enable long-term cell survival, maturation and differentiation. Nine of 28 (32%) immunosuppressed primates developed masses compatible with PTLD, located mainly in the gastrointestinal tract and/or nasal cavity. The masses were classified as monomorphic PTLD according to the WHO classification. Immunohistochemistry and PCR analyses revealed that the PTLDs were associated with macaca lymphocryptovirus as confirmed by double-labeling immunohistochemistry for CD20 and EBNA2, where the viral protein was located within the CD20-positive neoplastic B cells. In sera from three distinct phases of the experimental life of the primates, testing by quantitative PCR revealed a progression of the viral load that paralleled the PTLD progression, and no evidence of zoonotic transmission of porcine lymphotropic herpesvirus through xenoneuronal grafts. These data suggest that monitoring the variation of macaca lymphocryptovirus DNA in primates could be used as a possible early diagnostic tool for PTLD progression allowing pre-emptive treatment such as immunosuppression therapy reduction.

**Key words:** cynomolgus macaques, immunosuppression, Lymphocryptovirus, lymphoproliferative disorders, Parkinson's disease, xenotransplantation

Post-transplant lymphoproliferative disorders (PTLD) are a heterogeneous group of lymphoproliferative diseases that arise after transplantation of solid organ and other tissues.<sup>9</sup> They comprise a wide spectrum of clinical and pathological manifestations ranging from a benign self-limited form of lymphoproliferation to an aggressive and disseminated lymphoma.<sup>2</sup> PTLD incidence is as high as 10% in solid organ transplantation<sup>4</sup> and may occur at any time after transplantation, but the risk appears to be greatest within the first year post transplantation.<sup>19</sup> PTLD WHO classification recognizes three main pathologic subsets of the lymphoproliferative lesions: early, polymorphic, and monomorphic lesions.<sup>21</sup> Early lesions, more frequently involving tonsils, adenoids or lymph nodes than extranodal sites, include two morphological types: plasma cell hyperplasia and infectious mononucleosis-like lesions. Polymorphic PTLDs affect nodal and extranodal tissues and show loss of tissue architecture and necrosis. Polymorphic PTLDs are composed of a mixed population of immunoblasts, plasma cells, intermediate-sized lymphoid cells (incorporating a full range of B-cell morphology and differentiation), as well as occasional Hodgkin Reed Sternberg-like cells. Monomorphic PTLDs can be either of B cell or T-cell lineage, disturb the tissue architecture and spread to other organs. They are classified according to the WHO classification of lymphomas in immunocompetent patients, showing features of different morphologic variants of diffuse large B-cell lymphoma (DLBCL), Burkitt's lymphoma (BL), or plasmablastic lymphoma (PL).<sup>21</sup>

Approximately 50-80% of PTLD biopsies are positive for human herpesvirus 4 or Epstein Barr virus (EBV) within the tumor cells, reflecting the critical role of reduced cellular immuno-surveillance against EBV in its pathogenesis.<sup>18</sup>

EBV-related herpesvirus, or lymphocryptovirus (LCV) is similarly associated with lymphomas in immunosuppressed non-human primates (NHP).<sup>22</sup> In common with human EBV infection, primate LCV is endemic in Old World macaques, both those born in the wild and those raised in captivity, and resides latently in B cells in most adult animals.<sup>16</sup> Likewise, porcine lymphotropic herpesviruses (PLHV) are widespread among domestic pig populations<sup>5</sup> and have been associated with PTLD in pigs receiving allogeneic hematopoietic cell transplants.<sup>11</sup> Although the zoonotic potential of PLHVs is unknown, PLHV-related PTLD should be considered a risk in recipients of porcine derived xenografts. This small risk should be diminished by the use of specific pathogen free housed donor animals.<sup>10</sup>

Several reports have suggested that the use of cyclosporine in NHP, either alone or in combination with conventional immunosuppressive therapy, might be associated with an increased risk of lymphoma.<sup>16</sup> Malignant lymphomas were detected in two of five non-transplanted cynomolgus monkeys receiving cyclosporine and in simian immunodeficiency virus (SIV)-immunosuppressed cynomolgus and rhesus monkeys.<sup>13</sup> These lymphomas were mostly extranodal, aggressive and in all cases associated with LCV.<sup>16</sup> Endogenous LCV is capable of producing PTLD in immunosuppressed macaques that are recipients of kidney allografts with a frequency of 9 of 160 (5.6%).<sup>20</sup> Similarly, in a kidney xenotransplantation from pig to cynomolgus monkey and in kidney allotransplantation, LCV-related PTLD developed in 10 of 245 xenotransplanted (pig to cynomolgus monkey) (4%) and 9 of 231 (3,8%) allotransplanted primates.<sup>16</sup> The prevalence of PTLD is probably determined by the intensity of immunosuppression and not by the regimen used. The highest frequency of PTLD occurred in those animals that were on an aggressive immunosuppressive protocol,<sup>16</sup> and others have reported that there was no clear relationship between the

use of a particular drug or drug combination in maintenance of immunosuppression and the occurrence of PTLD.<sup>16</sup> Furthermore, a high dose regimen of cyclophosphamide and rapamycin led to a high incidence of PTLD in a life-supporting functional kidney and liver baboon-to-monkey grafts.<sup>23</sup> In a non-human primate model of facial composite tissue allotransplantation, a continuous infusion of tacrolimus provided prolonged rejection-free survival of the grafts. This was associated with a high frequency of donor-derived PTLD, possibly due to a large volume of transplanted vascularized bone marrow.<sup>3</sup> In summary, in humans the pathogenesis of PTLDs seems to be multifactorial: aside from the accumulation of genetic alterations of oncogenes and tumor suppressor genes, the role of EBV, among the possible infective causes, seems to be central in driving the proliferation of EBV-infected B cells and subsequent development of the lymphoproliferative disorder in the setting of a prolonged and profound immunosuppression which decreases the pool of specific cytotoxic T lymphocytes.<sup>7-21</sup>

In this study we characterize PTLD occurring in the setting of neural precursors xenotransplantation to treat a pharmacologically-induced form of Parkinson's disease (PD),<sup>1</sup> with respect to tissue localization, histopathology, immunophenotype and molecular viral transcript expression of primate LCV.

## Materials and Methods

### *Animals*

Twenty-eight, purpose-bred, 6- to 12-year-old, 20 females and 8 males, cynomolgus monkeys (*Macaca fascicularis*) from a breeding center in the Philippines, weighing between 2.7 and 6.5 kg, were included in this study. The primates were screened for zoonotic and simian diseases before joining the trial. Complete hematological and biochemical screening, fecal analysis for intestinal worms and protozoa, tuberculosis test and viral serology were also performed. All experiments and procedures were conducted in accordance with the Italian law (Law no. 116 of the 27/01/1992) and with the decree of the Ministry of Health 151/2007-C and finally approved by the CORIT (Consortium for Research in Organ Transplantation) Ethical Committee.

### *Experimental xenotransplant model*

In order to obtain a PD-like syndrome due to a progressive degeneration of the nigrostriatal dopaminergic system, all monkeys were treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) (Sigma, Saint Louis, MO, USA) by systemic administration, as described.<sup>1</sup> Once stable PD lesions were obtained, 24 monkeys were unilaterally injected in the left putamen with wild type (n=6) or CTLA4-Ig (n=18) transgenic neuronal precursors from pig embryos. All xenotransplanted primates were immunosuppressed for the whole duration of the study using a clinically applicable regimen: cyclosporine orally from day -2 to achieve 12 hours (hrs) through levels of 300 to 500ng/ml (Sandimmun Neoral, Novartis Pharma AG, Basel Switzerland), sodium mycophenolate from day +5 to achieve a 12 hrs through levels of 3 to 6 mg/ml, (Myfortic, Novartis Pharma AG), prednisone 1 mg/kg orally on days +1 and +2 post transplantation and then gradually decreased to 0.2 mg/kg/day



(Deltacortene, Hoechst Marion Roussel, Scoppito, Italy). In a group of animals (n=13), cyclosporine dosage was gradually decreased starting from day 100 post grafting to reach 12 hrs through levels of 50 to 100 ng/ml.<sup>1</sup> Xenograft survival and function was determined by clinical neurological assessment, analysis of locomotor activity (Ethovision software), brain imaging (MRI scan and <sup>18</sup>F-DOPA PET studies) and histological studies at the end of each experiment.<sup>1</sup>

### *Pathological study*

At the end of each experimental study or on the basis of their clinical condition, monkeys were euthanized and perfused transcardially with normal saline followed by 4% paraformaldehyde (Sigma, Saint Louis, MO, USA). The brains were removed and post-fixed for approximately 18 hrs in 4% paraformaldehyde and then cryopreserved by immersion in a graded (10-15-20%) sucrose/0.1M phosphate-buffered saline (pH 7.2) solution. Soon after euthanasia, collection of blood by aorta cannulation, cerebrospinal fluid by lumbar puncture, and bone marrow from femur were also performed. The primates underwent a complete post-mortem examination by a veterinary pathologist (LC) familiar with necropsies of transplanted primates, with pictures of every organ and lesion, and samples of all tissues were formalin-fixed as well as cryopreserved at -80°C. Paraffin-embedded, 3-4 µm thick sections were stained with hematoxylin and eosin and observed with a light microscope in a blinded manner, by two independent pathologists (LC and SW).

Additional investigations on neoplastic tissues from 9 of 28 primates included immunohistochemistry (IHC) using monoclonal antibodies with the following specificities: CD3 (dilution 1:100, clone PC3/188A, DAKO, Milan Italy), CD5 (dilution 1:50, clone 54/F6 DAKO), CD20 (dilution 1:50, clone L-26, BioGenex, Menarini, Florence Italy), CD79α (dilution 1:50, clone HM57, DAKO), a non-commercial

antibody specific for IE1 protein of rhesus CMV (courtesy of Prof. Peter Barry, California Medical Research Center, dilution 1:3000 and antigen retrieval at 95°C for 60 minute), pancytokeratin (dilution 1:100, clone AE1/AE3 M3515 DAKO), and vimentin (dilution 1:100, clone V9 DAKO). Sections (4 µm) were mounted on Superfrost® Plus microscope slides (Menzel GmbH, Braunschweig, Germany) and dried at 37°C for 30 min. All samples were tested with an automated immunostainer (Benchmark, Ventana Medical Systems Inc. Tucson, AZ), which included dewaxing and rehydration, antigen retrieval, primary antibody incubation, antigen detection with ultraView™ Universal Diaminobenzidine (DAB) kit (Ventana Medical Systems) and counterstaining with Mayer's haematoxylin. Finally, slides were manually dehydrated through a graded series of alcohols and mounted (Eukitt mounting medium, Fort Washington, PA). Primary antibody dilutions were performed using a commercial antibody diluent (Ventana Medical Systems).

For double-labeling IHC, formalin-fixed tissues were sectioned at 5 µm. Slides were deparaffinized, rehydrated and then blocked for peroxidase. Antigen retrieval was done in microwave by boiling in citrate buffer (pH 6.0) and cooling for 20 minutes at room temperature. Slides were then blocked sequentially for biotin and DAKO protein block. The slides were incubated with either CD20 (M0755, Dako, Carpinteria, CA) or CD3 (Pan T cell Pc #A0452, Dako) for 60' or 30' at room temperature, respectively, followed by biotinylated secondary for 30', and the Vector ABC Alkaline Phosphatase (Vector Labs, Burlingame, CA). Slides were incubated with the liquid permanent red for the cellular marker detection. Slides were then blocked sequentially for biotin, Mouse IgG Blocking Reagent (Vector Labs), Universal Block (KPL, Gaithersburg, MD), and DAKO protein block. Slides were then incubated overnight at 4°C with a monoclonal Epstein-Barr nuclear antigen 2

(EBNA2) antibody (NCL-EBV-PE2, Novocastra, Leica, Buffalo Grove, IL) followed by the biotinylated secondary antibody and Vector ABC peroxidase (Vector Labs). EBNA2 detection was performed with chromogen DAB (Dako). Slides were finally counterstained with Mayer's hematoxylin and coverslipped.

#### *Scoring for Ki-67 IHC*

Immunohistochemistry slides for Ki-67 were evaluated by a pathologist and scored on a 1+ to 4+ scale based on percent positivity assessed in 5 high power fields (1= <25%; 2= 25-50%; 3= %51-75%; 4 = >75%).

#### *Molecular study*

RNA extraction: Total RNA was extracted from PTLD and lymph node specimens using an RNeasy Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's specifications. The quality of the RNA was checked by gel electrophoresis on a 1% agarose gel containing SYBR Safe™ DNA Gel stain 10,000X (Invitrogen™, Carlsbad, California). RNA concentration was determined using a UV-Vis spectrophotometer, NanoDrop® ND-1000 (NanoDrop Technologies, Wilmington, USA).

Amplification of EBNA-1, EBNA-2 and Latent Membrane Protein 1 (LMP-1) cDNAs: a total of 300 ng of total RNA was reverse transcribed using a reverse transcriptase (Superscript II, Invitrogen) with random hexamers to obtain first-strand cDNA. The cDNA was then used as a template for the subsequent PCR reactions. Cycling conditions were: initial incubation at 94° C for 2 min followed by 45 cycles at 94°C for 30 s, annealing temperature for 40 s and 72°C for 40 s. A final extension step at 72°C for 5 min was added at the end of the last cycle. For each primer pair,

annealing temperature was set according to the predicted melting temperature. One fifth of each PCR reaction was electrophoresed on a 1.8% agarose gel, stained with SYBR Safe™ DNA Gel stain, and visualized under UV light. Primers for amplification of EBNA-1 and LMP-1 transcripts were designed according to Cynomolgus LCV sequences already stored on GenBank database ([www.ncbi.nlm.nih.gov](http://www.ncbi.nlm.nih.gov)) under accession numbers AB037276 and AAD56946, respectively (Supplemental Table 1). A first EBNA-2 fragment was amplified using degenerate primers designed on the basis of the multiple alignment of publicly available nucleotide sequences of three primates LCV transcripts: macacine EBNA-2 (*Macaca mulatta* Herpesvirus 4, AAK95414), papiine EBNA-2 (*Papio cynocephalus* Herpesvirus 1, AAA79034) and human EBNA-2 (Epstein-Barr virus, AAB89222). PCR products were then sequenced, and, based on sequenced fragment, a second PCR was carried out using a Reverse primer specific for Cynomolgus LCV (Mf\_EBNA2\_R, see Supplemental Table 1) and a Forward primer, designed as reported above, in order to increase the length of EBNA-2 sequence.

PLHV testing: DNA was prepared from porcine peripheral blood mononuclear cells (PBMCs) using the Qiagen DNeasy kit (Qiagen, Crawley, UK) according to manufacturer's instructions. Isolated DNA was then screened for the presence of PLHV by nested PCR using primer sets previously described.<sup>8</sup> All reactions were carried out using Core Taq PCR reagents (Qiagen, Crawley, UK).

Macaque Lymphocryptovirus (macLCV) screening: viral nucleic acid was isolated from the macaque sera using the PureLink viral RNA/DNA extraction kit (Life Technologies, Paisley, UK). Viral DNA preparations were screened for the presence of macLCV DNA by qPCR, using primers designed to correspond to the DPOL gene of macLCV (macLCVqPCR-F; 5'-GGACGTGCACTACAAGGAGA-3', macLCVqPCR-

R; 5'- GAATCYTGCACGCAGTACAT-3' and probe macLCVqPCR-P; 5'-6FAM-TCGCCTCTTTGCAGAGGGCC-TAMRA-3') and Taqman Gene Expression Master Mix reagents (Life Technologies, Paisley, UK). Amplification was achieved with 40 cycles of 95°C for 15sec, 53°C 15sec, 60°C 30sec and carried out alongside known copy number controls to allow quantification of each sample and to test reaction efficiency. All samples were spiked with an Internal Positive Control (Life Technologies, Paisley, UK) to test for the presence of inhibitory factors. The assay's limit of detection was 10 virus particles per ml of serum.

## **Results**

### *Pathological study*

Nine of 28 immunosuppressed macaques developed masses compatible with PTLD. Seven were recipients of neuronal precursors from CTLA4-Ig transgenic pig embryos, 1 from wild-type pig embryos and 1 received only MPTP treatment and immunosuppression. Clinical signs that led to euthanasia were related to the presence of a nasal mass (n=3), an abdominal mass (n=4), or both (n=2). Signs included respiratory noise, deviation of the nasal profile, abdominal pain and diarrhea. Clinical signs were detected from 110 to 287 post-operative days (POD) (average 172.5). Euthanasia was performed from 117 to 330 POD (average 192.5). Macroscopically, nasal masses had different levels of severity, tissue infiltration and size. The lesions ranged from diffuse bilateral thickening of nasal mucosa of both sides (n=2), to a distinct unilateral mass of 3 mm in diameter (n=1), to a complete unilateral to bilateral obliteration of the nasal cavity (n=1), with a wide extension from the ethmoid bone to the nostril and a marked deviation of the nasal septum and protrusion from the soft palate (n=2). In all subjects with abdominal pain, the bowel showed invaginations at different levels, especially in the small intestine. On cut

section, several button-like, 1- to 2-cm-diameter, ulcerated and protruding masses were detected, from gastric mucosa (n=1) to small intestine (n=2) or rectum (n=1). In addition, a moderate to severe (up to 6 cm in diameter) gastric, pancreatic and mesenteric lymph nodal enlargement was observed. In 50% of primates, other masses, possibly lymph nodes in origin, were found close to trachea, in the mediastinum, in the peritoneum or adjacent to thoracic or abdominal aorta. Only one case had a mass in another organ, the adrenal gland.

Microscopically, the masses were consistent with large-cell lymphomas composed of a diffuse atypical population of round cells, measuring up to 20  $\mu\text{m}$ , with scant to moderate eosinophilic cytoplasm, lacking distinct cell boundaries, located within the subepithelial connective tissue and occasionally in the epithelium of the nasal cavity, intestinal tract as well as many visceral lymph nodes. Occasionally the thoracic and visceral masses were severely effaced by the atypical population and a possible lymph nodal origin was considered. The cells were organized in broad sheets intermingled with a moderate fibrovascular stroma. The nuclei, 10-15  $\mu\text{m}$  diameter, were central, round to ovoid, frequently cleaved with finely granular chromatin and one prominent nucleolus. There were moderate anisokaryosis and anisocytosis. The mitoses were 5 to 20 in 10 high-power fields (Fig. 1 and 2) and scattered apoptotic cells were present. In the nasal masses (3 of 3 cases), the atypical population was associated with massive necrosis and destruction of the nasal bone. Scattered around the periphery of the masses were moderate, multifocal lymphoplasmacytic aggregates. As for the intestinal masses, in association with the atypical cells, focally extensive areas of necrosis and a peripheral rim of lymphocytes were present. A diffuse atypical population with the same features of other locations characterized the nodal masses. Based on cellular morphology and the rather homogenous

characteristics of all the nodal masses and the nasal and intestinal lesions, the diagnosis in the nine affected primates was of monomorphic PTLD according to the patterns described in the WHO classification.<sup>21</sup>

IHC revealed a uniform pattern of marker expression in all PTLD tumors examined. Neoplastic cells were consistent with B cells, diffusely labeling CD20 (Fig. 3) and CD79 and for vimentin intermediate filaments (data not shown for CD79 and vimentin). Neoplastic cells were negative for cytokeratins, CMV, CD3 and CD5 markers; however, CD3+ and CD5+ lymphocytes were scattered at the periphery of most tumors, occasionally infiltrating the neoplastic cells (data not shown for CD3 and CD5). Cellular proliferation, evidenced by expression of Ki-67, was high with greater than 50% positivity of the cells (based on at least 5 high power fields) for most PTLD tumors. Tumors from multiple sites in the same animal exhibited similar proliferation rates. A nasal cavity lymphoma in one primate had a low proliferation rate with <25% of cells Ki-67+ (based on at least 5 high power fields). EBNA2 labeling revealed a diffuse nuclear positivity of the tumors (Fig. 4).

Double-labeled IHC for CD20 and EBNA2 confirmed LCV infection of CD20-positive neoplastic cells of B cell origin (Fig. 5). In one case roughly 90% of EBNA2-positive neoplastic cells were CD20-positive B cells, while the remaining 10% were either B cells with down-regulated CD20 or were not B cells. In the same case, in another section, only 50% of the EBNA2-positive cells were positive for CD20, indicating a population of CD20-positive cells that were not LCV-infected. In another case, only 50% of the EBNA2-positive cells were positive for CD20, while 80% of CD20-positive B cells were positive for EBNA2. Double-labeling with CD3 and EBNA2 in this case failed to demonstrate that additional EBNA2 positive cells were CD3 lymphocytes (Fig. 6).

### *Molecular study*

A preliminary survey on EBNA-1, EBNA-2 and LMP-1 gene expression was carried out using end-point RT-PCR on neoplastic cells from five different PTLDs and two hyperplastic lymph nodes, confirmed at histology and immunohistochemistry, taken from PTLD affected primates. Gene-specific primers were used for both EBNA-1 and LMP-1 amplification, one primer pair for EBNA-1 while four different primer combinations were employed for LMP-1. EBNA-1 expression was demonstrated in all PTLD specimens by the amplification of a region of 453 bp showing a 98.6% identity with reference cynomolgus sequences in GenBank, while no expression was found in controls. Noticeably, four different RT-PCR assays failed to detect LMP-1 transcript in any of the specimens (Fig. 7). Degenerate primers designed on the multiple alignments of three primate EBNA-2 sequences allowed isolation of the cynomolgus LCV EBNA-2 transcript. The sequencing of two overlapping regions led to the assembly of a 832 bp sequence (GenBank accession number JQ845949). Sequence analysis revealed a 76% identity at the protein level with macacine herpesvirus 4 EBNA-2 (AAK95414), but considerably lower homology with human and papine counterparts, showing 49% and 33% identity respectively. The cynomolgus LCV EBNA-2 transcript in the present study showed a 99.3% identity at nucleotide level with the complete genome of a lymphocryptovirus isolated from cynomolgus monkey (NCBI accession number KP676001.1). EBNA-1, EBNA-2 transcripts were detected in all PTLD specimens, revealing viable virus in neoplastic cells, while no expression was observed in hyperplastic lymph nodes (Fig. 7).

DNA was isolated from PBMCs from the recipients and from the donor pigs. The DNA was screened by PCR for the presence of the porcine homologue to EBV, porcine lymphotropic herpesvirus (PLHV). PLHV was detected in 44% (n=9) of the



donor pool, but all recipients tested negative for PLHV. Pan-herpesvirus screening of the macaques and sequencing revealed the presence of the macaque homologue to EBV-macaque lymphocryptovirus (macLCV) in all recipients. A quantitative PCR assay was developed to detect macLCV and used to retrospectively screen viral DNA isolated from the serum of the macaques taken pre-transplant, at euthanasia and at intermediate time points post-transplant. The assay showed that the 9 PTLD-affected macaques had a detectable viremia within 36-278 days (mean  $117 \pm 30$  days) post-transplant and on average 60 days before the onset of clinical signs (Fig. 8). There was no detectable viremia in any of the 19 PTLD-unaffected macaques at any time point tested.

## **Discussion**

PTLD are a heterogeneous group of lymphoid proliferations that occur in the setting of depressed T-cell function due to immunosuppressive therapy used with solid organ transplantation or hematopoietic stem cell transplantation.<sup>9</sup> In humans, genetic and epigenetic alterations, microenvironment-resident plasmacytoid dendritic cells and Treg cells play a critical role, as well as viruses, notably EBV, and contribute to the development of PLTDs.<sup>21</sup>

The EBV genome exists in humans as an episome in latently infected B cells. Activated functional T-cells play a pivotal role in the control of proliferation and elimination of EBV-infected cells.<sup>15</sup> In immunocompromised subjects, T-cell function is impaired, which may lead to uncontrolled proliferation of EBV-transformed cells, known as EBV-related PTLD.<sup>12</sup> Most Old World NHP are infected with LCV, a herpesvirus of the same subgroup as EBV,<sup>22</sup> and several of the LCV products are homologues to EBV, such as EBNA and LMP.<sup>20</sup> A NHP xenotransplantation model

may have considerable potential value in elucidating PTLD pathogenesis and diagnosis. In this light, we characterized PTLD occurring in immunosuppressed cynomolgus monkeys undergoing neural precursor xenotransplantation to treat a pharmacologically induced form of PD.<sup>1</sup>

In our case series, PTLD occurred in 32% of animals after a long course of immunosuppressive therapy. In particular, we detected clinical signs related to the presence of nasal masses that led to difficulties in breathing, to abdominal masses that led to abdominal pain or both. Clinical signs occurred on average at 172.5 POD and the average time between the occurrence of clinical signs to euthanasia was 20 days. In the literature of NHP PTLDs, specifically in the context of solid organ xenotransplantation, different times of occurrence of this disorder are reported: a median of 6.5 and 33.5 POD in *Macaca fascicularis* models of renal xenotransplantation and renal allotransplantation respectively,<sup>16</sup> 28-103 POD in a model of renal transplantation,<sup>20</sup> after 6 months of intense immunosuppressive therapy in a rhesus macaque model of liver xenotransplantation or *Macaca fascicularis* model of kidney xenotransplantation,<sup>23</sup> and 60-177 POD in primates after composite facial allografts.<sup>3</sup> The present study is the first report of PTLDs occurring in the setting of neuronal precursor xenotransplantation in cynomolgus monkeys. All our primates were followed for six months after transplantation and immunosuppression and are considered long-term survivors. All PTLD cases in our study were lymphomas, assuming that the natural development of PTLD progresses from a non-neoplastic into a neoplastic lesion.

All above-mentioned publications from other laboratories have reported extranodal masses in xenotransplanted and immunosuppressed primates. In our animals, the principal locations were alimentary and upper respiratory tracts, possibly due to a

high density of MALT. In the abdominal cavity of primates with larger alimentary tract masses, disseminated enlargement of lymph nodes was observed. In addition, in half of the cases, other masses (possibly lymph nodes) were found close to trachea, in the mediastinum, or adjacent to thoracic or abdominal aorta.

Like most human PTLD and AIDS-related diseases, the NHP lymphomas are generally of high-grade malignancy.<sup>16</sup> The morphology of the masses of all xenotransplanted cynomolgus monkeys was similar, revealing a centroblastic diffuse B-cell lymphoma with high proliferation rate assessed with Ki67 immunolabeling. According to the most recent WHO classification of PTLD<sup>21</sup> these lymphomas are classified as monomorphic lymphomas.

In order to assess whether PTLDs are associated with LCV two different techniques were used, IHC and PCR. The IHC findings revealed that the neoplastic cells were diffusely positive for the EBNA2 viral protein. Double-labeling for CD20 and EBNA2 confirmed that LCV infection of CD20-positive neoplastic B cells.

When EBV infects a B lymphocyte, the virus expresses genes encoding proteins involved in viral DNA replication and viral particle synthesis. These include EBV nuclear antigens, EBNAs, and three latent membrane proteins (LMPs) associated with transforming activity.<sup>7</sup> In particular, EBNA-1 supports the EBV genome as a circular episome and is an important protein for immortalization and tumorigenesis of infected cells, and EBNA-2 stimulates B-cell proliferation through up-regulation of LMP1 and prevents reactivation from latency by upregulating the expression of LMP2. In addition, EBV proteins have properties that help avoid host immune responses. During latent infection, EBV-infected B cells are protected from apoptosis by LMP1. LMP1 is a CD40-mimic protein, which upregulates cellular Bcl-2, A20 and

other proteins that inhibit apoptosis and activates the NF- $\kappa$ B signaling pathway to stimulate cell growth. In humans, EBV-associated malignant diseases can be divided into three patterns of latency, depending on the viral genes expressed. In type III latency, all latency genes are expressed and development of PTLD occurs.<sup>6</sup> In our study, PCR revealed diffuse expression of EBNA-1 and EBNA-2 in neoplastic tissues, in comparison to reactive lymph nodes of the same animals. In contrast to what is observed in humans, we detected only the expression of EBNA-1 and EBNA-2 and not LMP-1 revealing a possible new pattern of viral protein expression during the development of PTLD in nonhuman primates.

In order to establish whether variation of viral DNA could be an early diagnostic tool for PTLD progression in primates, we designed a quantitative PCR that was used on sera of three distinct phases of the experimental life of our primates: pre-transplant, post-transplant (an intermediate time between transplantation and euthanasia) and euthanasia. EBV monitoring in humans suggests that high EBV loads are only predictive of PTLD if associated with low cytotoxic T cell responses. Instead, in the present study, the data suggest that macLCV monitoring may be valuable in the early detection of PTLD in non-human primate xenotransplantation trials, allowing pre-emptive treatment such as a reduction of immunosuppression therapy. In addition, there was no evidence of PLHV zoonotic transmission through xenoneuronal grafts in this study.

In conclusion, even if a systemic immunosuppression was needed to sustain the life of a neuronal cell graft in this Parkinson's disease xenotransplantation model, PTLD occurred in a third of the immunosuppressed *Macaca fascicularis* recipients of the graft. Incomparable to human transplant patients, PTLD is related to the presence of lymphocryptovirus in primates as demonstrated by the detection of viral proteins in

neoplastic cells. Interestingly, serologic screening of the viral DNA load in the recipients during the post transplantation phase ruled out a possible donor-derived infection. The clinical application of viral DNA monitoring could be of help in identifying a possible early onset of the disease and a consequent adjustment of the immunosuppressive regimen could be applied.

### **Acknowledgments**

People involved in XENOME project (European Commission's Sixth Framework Program, under the priority thematic area Life Sciences, Genomics and Biotechnology for Health, contract N°. LSHB- CT- 2006- 037377). Dr. Peter Barry (California Medical Research Center) for providing the non-commercial antibody specific for IE1 protein of Rhesus CMV. The CORIT (Consortium for Research in Organ Transplantation, Padua, Italy) primates' keepers (Daniele Ramon, Andrea Barzon) and veterinary staff (Fabio Fante, Massimo Boldrin) for the invaluable support and care. Dr. Giuseppe Palmisano and Emanuele Zanetti (BCA Dept, Padua University) for post mortem room technical help. Dr. Silvia Ferro for the editing support.

### **Declaration of Conflicting Interests**

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

### **Funding**

The author(s) received no financial support for the research, authorship, and/or publication of this article.

## References

1. Aron Badin R, Vadori M, Vanhove B, et al. Cell therapy for Parkinson's disease: a translational approach to assess the role of local and systemic immunosuppression. *Am J Transplant*. 2016;Epub ahead of print.
- 2- Aversa SM, Stragliotto S, Marino D, et al. Post transplant lymphoproliferative disorders after heart or kidney transplantation at a single centre: presentation and response to treatment. *Acta Haematol*, 2008;120(1):36-46.
3. Barth RN, Nam AJ, Stanwix MG, et al. Prolonged Survival of Composite Facial Allografts in Non-Human-Primates associated with posttransplant lymphoproliferative disorder. *Transplantation*. 2009;88:1242-1250.
4. Burns DM, Crawford DH. Epstein-Barr virus-specific cytotoxic T-lymphocytes for adoptive immunotherapy of post-transplant lymphoproliferative disease. *Blood Rev*. 2004;18(3):193-209.
5. Chmielewicz B, Goltz M, Franz T, et al. A novel porcine gammaherpesvirus. *Virology*. 2003;308:317-32.
6. Cohen JL. Epstein-Barr virus infection. *N Engl J Med*. 2000;343:481-492
7. Cohen JL, Bollard CM, Khanna R, Pittaluga S. Current understanding of the role of Epstein-Barr virus (EBV) in lymphomagenesis and therapeutic approaches to EBV-associated lymphomas. *Leuk Lymphoma*. 2008;49:27-34.

8. Ehlers B, Ulrich S, Goltz M. Detection of two novel Porcine Herpesviruses with high similarity to Gammaherpesviruses. J Gen Virol. 1999;80:971-978.
9. Evens AM, Roy R, Sterrenberg D, Moll MZ, Chadburn S, Gordon LI. Post-transplantation lymphoproliferative disorders: diagnosis, prognosis and current approaches to therapy. Curr Oncol Rep. 2010;12:383-394.
10. Fishman JA, Patience C. Xenotransplantation: infectious risk revisited. Am J Transplant. 2004;4:1383-1390.
11. Huang CA, Fuchimoto Y, Gleit ZL, et al. Post transplantation lymphoproliferative disease in miniature swine after allogeneic hematopoietic cell transplantation: similarity to human PTLD and association with a porcine gammaherpesvirus. Blood. 2001;97:1467-1473.
12. Jagadeesh D, Woda BA, Draper J, Evens AM. Post transplant lymphoproliferative disorders: risk, classification and therapeutic recommendations. Curr Treat Option in On. 2012;13:122-136.
13. Kahnt K, Matz-Rensing K, Hofmann P, Stahl Henning C, Kaup FJ. SIV-associated lymphomas in Rhesus Monkeys (*Macaca mulatta*) in comparison with HIV-associated lymphomas. Vet Pathol. 2002;39:42-55.

14. Kulak JM, Schneider JS. Differences in alpha 7 nicotinic acetylcholine receptor binding in motor symptomatic and asymptomatic MPTP-treated monkeys. *Brain Res.* 2004;999(2):193-202.
15. Loren AW, Porter DL, Stadtmauer EA, Tsai DE. Post transplantation lymphoproliferative disorder: a review. *Bone marrow Transpl.* 2003;31:145-55.
16. Mc Innes E, Jarrett RF, Langford G, et al. Post transplant lymphoproliferative disorder associated with gamma-herpesvirus in Cynomolgus monkeys used in pig-to-primate renal xenotransplantation and primate renal allotransplantation. *Transplantation.* 2002;73:44-52.
17. Moghaddam A, Rosenzweig M, Lee.Parriz D, Annis B, Johnson RP, Wang F. An animal model for acute and persistent Epstein-Barr virus infection. *Science.* 1997;276:2030-2033.
18. Nourse JP, Jones K, Gandhi MK. Epstein-Barr Virus-related post-transplant lymphoproliferative disorders: pathogenic insights for targeted therapy *Am J Transplant.* 2011;11(5):888-95.
19. Opelz G, Dohler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. *Am J Transplant.* 2004;4(2):222-30.



20. Schmidtko J, Wang R, Wu CL, et al. Posttransplant lymphoproliferative disorder associated with Epstein-Barr related virus in cynomolgus monkeys. *Transplantation*. 2002;73:1431-1439.
21. Swerdlow SH, Webber SA, Chadburn A, Ferry JA. Post-transplant lymphoproliferative disorders. In: Swerdlow SH, Harris NL, Jaffe ES. et al. WHO classification of Tumors of Haemopoietic and Lymphoid tissues. Lyon; 4<sup>th</sup> ed. IARC; 2008:343-350.
22. Wang F. Nonhuman primate models for Epstein-Barr virus infection. *Curr Opin Virol*. 2013;3(3):233-237
23. Zhong R, Tucker J, Zhang Z, et al. The long-term survival of baboon-to-monkey kidney and liver xenografts. *Xenotransplantation*. 2003;10(5):398-409.

## FIGURE LEGENDS

### **FIGURE 1-6 Monomorphic PLTD, nasal cavity, *Macaca fascicularis*: 1 HE.**

Diffuse and dense cellular population. **2** Same cellular population as 1, HE. The cells, 20 µm are round with scant eosinophilic cytoplasm with no distinct cell boundaries. The nuclei, 10-15 µm are central, round to ovoid, with finely granular chromatin and one prominent nucleolus. Occasional mitoses are present (arrows). **3** IHC for CD20, shows a diffuse brown cytoplasmic positivity for neoplastic cells. **4** IHC for EBNA2, shows a diffuse brown nuclear positivity for neoplastic cells. **5** Double-labeled IHC for CD20 (cytoplasmic, brown) and EBNA2 (nuclear, red), shows a diffuse double, cytoplasmic and nuclear positivity confirmed LCV infection of CD20 positive neoplastic cells. **6** Double-labeled IHC for CD3 (membranous, brown) and EBNA2 (nuclear, red), shows scattered CD3 positive cells among EBNA2 nuclear-positive cells.

**FIGURE 7:** RT-PCR analysis of cynomolgus EBNA-1, EBNA2 and LMP-1 mRNA expression. Samples P1, P2, P3, P4 and P5 are Post Transplant Lymphoproliferative Disorder positive (PTLD+) primates; samples L4 and L5 are hyperplastic lymph nodes from P4 and P5 PTLD+ primates. M, molecular marker; C No Template Control. EBNA-1, EBNA-2 transcripts are detected in all PTLD specimens, while no expression is observed in hyperplastic lymph nodes.

**FIGURE 8:** Lymphocryptovirus (LCV) viremia levels in Post-Transplant Lymphoproliferative Disorder (PTLD) affected animals. No viremia was detected in PTLD-negative animals.